Adenocarcinoma of the prostate is the most common cancer diagnosed in men with approximately one in nine men diagnosed in their lifetime. Current screening methods impose substantial laboratory workload and suffer from intra and inter-observer variability, poor reproducibility and potential misses of small cancers.
AI-based diagnostic support solutions are being implemented and may improve diagnostic accuracy, reproducibility and efficiency.
This study tested the use of an artificial intelligence (AI)-based solutions, Galen™ Prostate (Ibex Medical Analytics) for primary diagnosis of prostate adenocarcinoma using real-world data.
Click here to download the study:Back